# Apollomics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/apollomics

- Industry: Biotechnology
- Headquarters: Foster City, US
- Website: www.apollomicsinc.com
- Total disclosed funding: $232M
- Latest round: Series C (Nov 6, 2020)
- Investors on record: 4

## About

Apollomics, Inc. is a biotechnology company focused on developing innovative oncology combination therapies that harness the immune system and target molecular pathways to combat cancer effectively.Founded in 2016, Apollomics, Inc. is headquartered in Foster City, US, specializing in the development of cancer therapies. The company was involved in a merger with Maxpro Capital Acquisition Corp., raising USD 21.35 mn in February 2023. Sanjeev Redkar is the founder, who has a background in the biotech sector.Apollomics, Inc. specializes in the discovery and development of oncology combination therapies, focusing on leveraging the immune system and targeting specific molecular pathways to inhibit cancer progression. The company's core product offerings include Vebreltinib (APL-101), Uproleselan (APL-106), APL-102, and APL-501, which aim to treat various forms of cancer, particularly for patients who have exhausted standard treatment options.Apollomics generates revenue through partnerships and collaborations in the biotechnology sector, particularly focusing on oncology therapies. The company engages in strategic partnerships with healthcare providers, research institutions, and pharmaceutical companies. These collaborations often involve licensing agreements and joint ventures, structured around milestone payments, royalties on sales, or upfront fees, although specific pricing plans for individual products have not been disclosed.In February 2023, Apollomics, Inc. agreed to merge with Maxpro Capital Acquisition Corp., a SPAC vehicle, for USD 21.35 mn. The company plans to leverage this funding to expand its product offerings and explore new markets, particularly targeting regions in North America, Europe, and Asia. Details regarding specific upcoming products or timelines for market entry have not been disclosed.

## Funding rounds

- Series C, Nov 6, 2020, $124M — OrbiMed Advisors, Crown Bioscience, Inc., CMB International Asset Management, Ping An Capital
- Series B, Jan 7, 2019, $100M — OrbiMed Advisors, CMB International Asset Management
- Series A, Aug 29, 2016, $7.8M — OrbiMed Advisors

## Investors

- OrbiMed Advisors (https://capitalatlas.ai/funds/orbimed-advisors) — Series A, Series B, Series C
- CMB International Asset Management (https://capitalatlas.ai/funds/cmb-international-asset-management) — Series B, Series C
- Crown Bioscience, Inc. — Series C
- Ping An Capital — Series C